BXP, Inc. (NYSE: BXP) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by unconsolidated joint ventures, BXP's portfolio totals 53.3 million square feet and 185 properties, including seven properties under construction/redevelopment.

BXP Inc.

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an announcement. Botanix Pharmaceuticals has disclosed a change in the interests of dire...

Botanix Director Granted Options Linked to Share Placement

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on BXP (BXP), Regency Centers (REG) and AGNC Investm...

Analysts Have Conflicting Sentiments on These Real Estate Companies: BXP (BXP), Regency Centers (REG) and AGNC Investment (AGNC)

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an update. Botanix Pharmaceuticals has opened registration for an investor webinar to b...

Botanix Opens Investor Webinar to Detail Sofdra Progress and Quarterly Performance

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals has notified the market of the issue of ...

Botanix Issues 773 Million Unlisted Options at $0.06 Expiring 2027

An update from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals has applied for quotation on the ASX of 83,3...

Botanix Seeks ASX Quotation for 83 Million New Shares

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has shared an announcement. Botanix Pharmaceuticals has notified the market that a total of 6.5 milli...

Botanix options lapse, trimming potential share dilution

In a report released yesterday, from Wells Fargo maintained a Buy rating on BXP, with a price target of $85.00. The company’s shares closed yesterd...

BXP (BXP) Gets a Buy from Wells Fargo

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an announcement. Botanix Pharmaceuticals has applied for quotation of 160,000 new fully ...

Botanix Seeks ASX Quotation for 160,000 New Ordinary Shares

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals has applied to the ASX for quotation of ...

Botanix Seeks ASX Quotation for 3.6 Million New Shares

In a report released today, Ronald Kamdem from Morgan Stanley reiterated a Hold rating on BXP, with a price target of $60.00. Kamdem covers the Rea...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BXP	$58.19	+0.80%	1.55M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BXP	$58.19	+0.8%	1.55M
3
4
5
6

BXP

BXP

Get BXP Inc. Data in Excel

Get BXP Inc. Data in Excel